Marker Therapeutics Inc (MRKR)

[microcapbiotech]

OK, the last 16 months have been a ride. In June 2018, we were told the market cap, post merger would be 1 billion.
At that time 300 million seemed more reasonable, but now, here we are at less than 200 million, and that is after GOOD news on pancreatic cancer.

We got two months left in the year before tax loss selling season. HOPEFULLY before the end of the year, we get some info on TPIV legacy trials (after all, that's what most of us actually invested in before Marker came along), and also, hopefully, maybe, possibly, potentially, get some more good pancreatic news/update.

That would be nice.